药品管理新规五月实施，明确4条药品加快上市通道

Core Viewpoint - The newly revised "Regulations on the Implementation of the Drug Administration Law of the People's Republic of China" introduces significant changes aimed at accelerating the drug approval process and enhancing intellectual property protection for pharmaceuticals, effective from May 15, 2026 [1] Group 1: Accelerated Drug Approval - The revised regulations establish four accelerated pathways for drug approval: breakthrough therapy drugs, conditional approval, priority review, and special approval [1] - These pathways are now clearly defined within administrative regulations for the first time in 23 years [1] Group 2: Intellectual Property Protection - The new regulations expand the drug trial data protection system and introduce a market exclusivity period for certain drugs [1] - The market exclusivity period is set to protect drugs for rare diseases and pediatric use, with a maximum of 2 years for pediatric drugs and up to 7 years for rare disease drugs [1]